通过双点相互作用,有效地破坏使用Zn(II) 二聚胺基人工受体的脂蛋白-蛋白表面相互作用
Akio Ojida1, Masa-aki Inoue, Yasuko Mito-oka
1Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Katsura, Kyoto, 615-8510, Japan.
Journal of the American Chemical Society
|February 9, 2006
概括
研究人员开发了结合双酸化的小分子,破坏了蛋白与蛋白的相互作用. 这种新的策略显示出创造蛋白质信号通路的向抑制剂的前景.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 化学生物学 化学生物学
背景情况:
- 蛋白质酸化对于细胞信号传递和蛋白质与蛋白质相互作用至关重要.
- 不调节的蛋白相互作用与各种疾病有关.
研究的目的:
- 为了研究双核Zn(II) -Dpa受体与二化的结合.
- 使用这些小分子来证明蛋白-蛋白相互作用的破坏.
主要方法:
- 异热定位热量计 (ITC) 用于结合量化.
- 诱导循环二元化 (CD) 和核磁共振 (NMR) 用于相互作用分析.
- 测试化CTD和Pin1 WW域相互作用的破坏.
主要成果:
- 双核Zn(II) -Dpa受体通过交叉链接结合双化.
- 结合取决于Zn (II) 中心和酸盐组之间的空间适合.
- 在微分子度下实现的光蛋白-蛋白相互作用的破坏.
结论:
- 小分子受体可以有效地准和破坏光蛋白-蛋白相互作用.
- 这种方法为开发新型蛋白-蛋白相互作用抑制剂提供了一个独特的策略.
- 这些发现对信号相关疾病的治疗开发有意义.
相关概念视频
Phosphoinositides and PIPs
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...


